Evidence for neuropeptide Y synthesis in the rat anterior pituitary and the influence of thyroid hormone status: comparison with vasoactive intestinal peptide, substance P, and neurotensin.

Jones PM, Ghatei MA, Steel J, O'Halloran D, Gon G, Legon S, Burrin JM, Leonhardt U, Polak JM, Bloom SR

Endocrinology1 Jul 1989Cited by 62 (Europe PMC)

PMID2472269DOI10.1210/endo-125-1-334PepBankPUB-02472269

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In rats, hypothyroidism increased the body's own pituitary VIP content.
In plain wordsIn rats, an underactive thyroid raised the body's own VIP content in the pituitary gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePituitary VIP content in hypothyroidism
Study
ratn: not reported in source
rat anterior pituitary, peptide by RIA and mRNA
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
Hypothyroidism was found to significantly increase the pituitary content of NPY, SP, and VIP and their respective mRNAs but to decrease the quantity of NT.
1 context sentence(design, population, supporting numbers)
Summary · context
Three other anterior pituitary neuropeptides, neurotensin (NT), substance P (SP), and vasoactive intestinal peptide (VIP), were studied for comparison.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0247226901
02AnimalEndogenous levelAnimal study (in vivo)Other
In rats, hypothyroidism increased the pituitary VIP mRNA level.
In plain wordsIn rats, an underactive thyroid raised the activity of the gene for the body's own VIP in the pituitary gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePituitary VIP mRNA in hypothyroidism
Study
ratn: not reported in source
rat anterior pituitary, peptide by RIA and mRNA
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
Hypothyroidism was found to significantly increase the pituitary content of NPY, SP, and VIP and their respective mRNAs but to decrease the quantity of NT.
1 context sentence(design, population, supporting numbers)
Summary · context
Three other anterior pituitary neuropeptides, neurotensin (NT), substance P (SP), and vasoactive intestinal peptide (VIP), were studied for comparison.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0247226902
03AnimalEndogenous levelAnimal study (in vivo)Other
In rats, thyroxine-induced hyperthyroidism did not affect pituitary VIP levels.
In plain wordsIn rats, an overactive thyroid did not change the body's own VIP level in the pituitary gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePituitary VIP in T4-induced hyperthyroidism
Study
ratn: not reported in source
rat anterior pituitary, peptide by RIA and mRNA
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
In T4-induced hyperthyroidism NPY, NT, and VIP levels were unaffected
1 context sentence(design, population, supporting numbers)
Summary · context
Three other anterior pituitary neuropeptides, neurotensin (NT), substance P (SP), and vasoactive intestinal peptide (VIP), were studied for comparison.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0247226903
04AnimalEndogenous levelAnimal study (in vivo)Other
In rats, TRH treatment had no effect on pituitary VIP.
In plain wordsIn rats, TRH treatment did not change the body's own VIP in the pituitary gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePituitary VIP after TRH treatment
Study
ratn: not reported in source
rat anterior pituitary, peptide by RIA and mRNA
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
TRH treatment produced a decrease in NT and had no effect on NPY, SP, or VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
Three other anterior pituitary neuropeptides, neurotensin (NT), substance P (SP), and vasoactive intestinal peptide (VIP), were studied for comparison.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0247226904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.